Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

PegIntron and Rebetol (peginterferon alfa-2b and ribavirin)


Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- March 2008

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.


Summary View

Sections Modified

ADVERSE REACTIONS

  • The adverse event profile in Study 3...

MEDICATION GUIDE

  • The most serious possible side effects of Peglntron and PegIntron/Rebetol therapy include:
    • Body Organ Problems
  • Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Label not available on Drugs@FDA

-
-